Fsd Pharma (TSE:HUGE) has released an update.
FSD Pharma has partnered with ASPI to launch a clinical trial in the U.S. to evaluate the efficacy and safety of their dietary supplement, unbuzzd™, which aims to counteract alcohol intoxication. The METAL-2 trial will test the supplement’s ability to reverse alcohol effects against a placebo with thirty volunteers. This research aims to solidify FSD Pharma’s position as a frontrunner in addressing alcohol intoxication through innovative products.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
